uniQure N.V. (QURE) Stock Price & Analysis
uniQure N.V. (QURE) closed at USD 25.3 on Thursday, October 29, 2026, up 1.32% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 24.97; the Oct 29, 2026 session ranged USD 24.6–25.99 on volume of 1,713,272 shares. Market capitalization is $1.75B, with a 52-week range of USD 8.73–69.99 (NMS). Source: Nexqual, retrieved October 29, 2026 at 22:04 UTC.
Also available as compact Markdown for AI agents: nexqual.com/QURE.md
Key facts (QURE)
- Last four reported quarters (through Jun 30, 2026): revenue $18.7M, net income -$252M (-1350.7% margin), free cash flow -$161M (SEC filings).
- Analysts: Buy (mean 2.08 on a 1–5 scale) (13 analysts), mean target USD 60.28 (range 27.94–91.38).
- Total return with dividends: 1Y -62.7% vs S&P 500 +14.4%; 5Y -17.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.82, revenue estimate $5.4M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: QURE paid no cash dividend in the last five years.
- Short interest: 12.75% of float (as of 2026-10-15), 2.5 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (QURE)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $524M | $106M | $15.8M | $27.1M | $16.1M | $18.7M |
| Gross profit | $499M | $105M | $15.8M | $25.9M | $14.4M | — |
| Operating income | $311M | -$143M | -$283M | -$184M | -$185M | -$200M |
| Net income | $330M | -$127M | -$308M | -$240M | -$199M | -$252M |
| EPS (diluted) | $7.04 | -$2.71 | -$6.47 | -$4.92 | -$3.46 | — |
| Free cash flow | $271M | -$163M | -$153M | -$186M | -$178M | -$161M |
| Gross margin | 95.2% | 98.8% | 99.6% | 95.3% | 89.5% | — |
| Operating margin | 59.3% | -134.4% | -1785.5% | -679.6% | -1151.4% | -1071.5% |
| Net margin | 62.9% | -119.1% | -1947.1% | -883.4% | -1236.0% | -1350.7% |
| Revenue growth | +1296.8% | -79.7% | -85.1% | +71.2% | -40.6% | — |
| Cash + short-term investments | $556M | $228M | $618M | $368M | $623M | — |
| Total debt | $136M | $144M | $148M | $66.0M | $71.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (QURE)
P/S 94.0x · EV/Sales 53.3x · P/B 5.4x · FCF yield -9.20% · Earnings yield -14.37% · Net cash $760M · EV $995M
Analysts (QURE)
Consensus Buy (mean 2.08 on a 1–5 scale), 13 analysts; mean target USD 60.28 (low 27.94, high 91.38).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | Barclays | Downgrade | Overweight → Equal-Weight | $60 → $28 |
| 2026-10-02 | RBC Capital | Target lowered | Outperform | $65 → $48 |
| 2026-09-30 | Goldman Sachs | Target lowered | Neutral | $46 → $31 |
| 2026-07-30 | Wells Fargo | Target raised | Overweight | $60 → $75 |
| 2026-07-30 | Wolfe Research | Upgrade | Peer Perform → Outperform | $65 |
| 2026-07-30 | Barclays | Target lowered | Overweight | $65 → $60 |
Total return (dividends reinvested) (QURE)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -62.7% | -17.0% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -62.8% | -3.6% |
| Volatility (annualized) | 144.7% | 120.0% |
| Max drawdown | -86.7% (Oct 2025→Mar 2026) | -89.1% (Nov 2021→Jul 2024) |
Dividends (QURE)
QURE paid no cash dividend in the last five years.
Short interest (QURE)
8,726,589 shares sold short, 12.75% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 9,920,512 shares (-12.0%). Days to cover: 2.5 (short shares ÷ average daily volume).
QURE earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Jul 29, 2026 | Quarter ended Jun 30, 2026 | −$1.07 | −$0.71 | Miss −50.7% | +15.1% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | −$0.73 | −$0.75 | Beat +2.7% | +10.3% |
| Mar 2, 2026 | Quarter ended Dec 31, 2025 | −$0.47 | −$0.78 | Beat +39.7% | -42.2% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | −$1.19 | −$0.75 | Miss −58.7% | +11.0% |
| Jul 29, 2025 | — | — | — | — | -3.5% |
| May 9, 2025 | — | — | — | — | +7.3% |
| Feb 27, 2025 | — | — | — | — | +12.7% |
| Nov 5, 2024 | — | — | — | — | +28.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
QURE revenue by product line (quarter ended Sep 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| License | $3.6M | 96.8% | +69.7% |
| Collaborative Revenue | $119,000 | 3.2% | -32.4% |
| Total revenue | $3.7M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
QURE company outlook (results filed Jul 29, 2026)
- “With four-year data expected in September and the U.K. regulatory activities progressing as planned, we enter the second half of 2026 with real momentum and a clear line of sight to potentially bringing this therapy to the people who need it." "Beyond AMT-130, we continue to execute across our broader pipeline," Mr.”
- “No immunosuppression was required. ● The Company expects to complete enrollment in the second dose cohort in the Phase I/IIa study in the third quarter of 2026. ● The Company expects to present updated results from the Phase I/IIa study in the first half of 2027.”
- “The Company expects that these resources will be sufficient to fund projected operating expenses into 2030.”
- “The Company expects that these resources will be sufficient to fund our projected operating expenses into 2030.”
Quoted word-for-word from the SEC 8-K results press release.
QURE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.82 | $-0.81 | −$0.01 | $5.4M | 11 |
| Next quarter (ends Dec 2026) | $-0.81 | $-0.93 | +$0.11 | $6.8M | 11 |
| Current fiscal year (ends Dec 2026) | $-3.44 | $-3.16 | −$0.28 | $21.1M | 11 |
| Next fiscal year (ends Dec 2027) | $-2.64 | $-2.53 | −$0.12 | $96.2M | 11 |
QURE options: expected move
Options price a move of about ±23.5% (±$5.95) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±16.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 121.0% | ±23.5% |
| Dec 18, 2026 | 50 | 95.0% | ±27.9% |
| Jan 15, 2027 | 78 | 87.5% | ±31.8% |
| Feb 19, 2027 | 113 | 96.6% | ±42.1% |
| Mar 19, 2027 | 141 | 102.8% | ±49.8% |
| Apr 16, 2027 | 169 | 117.1% | ±61.5% |
| May 21, 2027 | 204 | 118.7% | ±67.8% |
30-day implied volatility 105.9% vs 148.3% realized over the last 30 trading days. Put/call ratio (volume) 0.05. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 22:04 UTC)
| Price | USD 25.3 |
|---|---|
| Change | ▲ 1.32% (up) |
| Previous Close | USD 24.97 |
| Open | USD 24.86 |
| Day Range | USD 24.6 – 25.99 |
| 52-Week Range | USD 8.73 – 69.99 |
| Volume | 1,713,272 shares |
| Market Cap | $1.75B |
| Exchange | NMS |
Technical Analysis (QURE)
Nexqual's technical model rates QURE "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 22:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.14 (neutral) |
| vs SMA50 | Below (USD 35.04) |
| MACD | -2.79 (negative) |
Analyst Ratings (QURE)
Wall Street analysts rate QURE "Buy" based on 13 analysts, with a mean price target of USD 60.28 (range USD 27.94–91.38), per Nexqual as of October 29, 2026 at 22:04 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 60.28 |
| High Target | USD 91.38 |
| Low Target | USD 27.94 |
| Buy / Hold / Sell | 11 / 2 / 0 |
Earnings (QURE)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.82 |
| Revenue Estimate | $5.43M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.07 vs est -0.71 ▼ miss |
| 2026-03-31 | USD -0.73 vs est -0.75 ▲ beat |
| 2025-12-31 | USD -0.47 vs est -0.78 ▲ beat |
| 2025-09-30 | USD -1.19 vs est -0.75 ▼ miss |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
Financials & Fundamentals (QURE)
| Total Revenue | $18.67M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +11.00% |
| Gross Margin | +0.00% |
| Operating Margin | -872.23% |
| Profit Margin | +0.00% |
| ROE | -157.61% |
| Debt / Equity | 1.7 |
| Current Ratio | 10.01 |
| Total Cash | $810.33M |
| Total Debt | $552.17M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$161.45M (-864.7% of revenue) |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
Financial Health Score (QURE)
Nexqual rates uniQure N.V.'s overall financial health "Critical" across five dimensions, as of October 29, 2026 at 22:04 UTC.
| Growth | Critical — Revenue -48% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $810M cash and investments vs $50M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$161M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -78%, ROA -25.6% (last 4 quarters, SEC) |
Ownership (QURE)
| Insider Ownership | +1.26% |
|---|---|
| Institutional Ownership | +98.15% |
| Shares Outstanding | 69.37M |
| Float | 57.52M |
| Short % of Float | +12.75% |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
Leadership (QURE)
uniQure N.V. is led by Matthew Craig Kapusta, CEO & Executive Director, per Nexqual as of October 29, 2026 at 22:04 UTC.
| CEO & Executive Director | Matthew Craig Kapusta |
|---|---|
| CFO, Principal Financial Officer & GM of Amsterdam Site | Christian Klemt |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | Hugo Katus |
| Senior Director of Investor Relations | Chiara Elizabeth Russo |
| Business Development Director | Tamara Tugal |
Major Backers & Investors (QURE)
Notable institutional backers of uniQure N.V. include Avoro Capital Advisors LLC, JPMorgan, RTW Investments LP, according to Nexqual as of October 29, 2026 at 22:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 9.7% |
| JPMorgan | 7.02% |
| RTW Investments LP | 5.68% |
| Aberdeen Group plc | 4.11% |
| Orbimed Advisors LLC. | 2.61% |
| abrdn Healthcare Investors | 2.51% |
| Jane Street Group, LLC | 2.32% |
| Jennison Associates LLC | 2.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 4.19% |
| BlackRock | 2.71% |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
From uniQure N.V.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- We strive to protect the proprietary technologies that we believe are important to our business, including by seeking and maintaining patent protection in the U.S., Europe, and other jurisdictions for novel components of our gene therapies, the chemistries of and processes for manufacturing these gene therapies, the use of these components in gene therapies, our technology platform, and other inventions and technology.
- We seek to protect our proprietary technology and processes and obtain and maintain ownership of certain technologies, in part, through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial collaborators.
- In the U.S., the FDA regulates biologics under the Public Health Service Act ("PHSA") and the Federal Food, Drug, and Cosmetic Act ("FDCA") and regulations and guidance implementing these laws.
- AMT-130 is our novel gene therapy candidate for the treatment of Huntington's disease, which utilizes our proprietary, gene-silencing miQURE platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment.
Partnerships
- In 2015, we entered into a license agreement with CSHL in which CSHL granted to us an exclusive, sublicensable license to develop and commercialize certain of CSHL's patented RNAi-related technology for use in connection with the treatment or prevention of Huntington's disease.
- In June 2020, we entered into a commercialization and license agreement with CSL Behring LLC (the "CSL Behring Agreement") pursuant to which CSL Behring LLC ("CSL Behring") received exclusive global rights to HEMGENIX.
Legal & Regulatory Risks (Item 1A, quoted)
- The process of obtaining marketing approval for our product candidates in the U.S., the EU, UK and other countries is expensive and may take many years, if approval is obtained at all.
- We may leverage certain specialized regulatory pathways and designations, such as the FDA's accelerated approval pathway, RMAT designation and Breakthrough Therapy designation, to develop our product candidates or to seek licensure.
- Our failure to obtain or maintain orphan product exclusivity for any of our product candidates for which we seek this status could limit our commercial opportunity, and if our competitors are able to obtain orphan product exclusivity before we do, we may not be able to obtain approval for our competing products for a significant period.
- Regulatory authorities in some jurisdictions, including the U.S., the EU, and the UK, may designate drugs for relatively small patient populations as orphan drugs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| KOD | Kodiak Sciences Inc | USD 100.4 | ▲ 3.46% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:04 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt